REFERENCES
- Chakraborty, N., & Johnston, T. (2004). Aripiprazole and neuroleptic malignant syndrome. International Clinical Psychopharmacology, 19, 351–353.
- Desarkar, P., Thakur, A., & Sinha, V. K. (2006). Aripiprazole-induced acute dystonia. The American Journal of Psychiatry, 163, 1112–1113.
- Fernandez, H. H., Trieschmann, M. E., & Friedman, J. H. (2004). Aripiprazole for drug-induced psychosis in Parkinson disease: Preliminary experience. Clinical Neuropharmacology, 27, 4–5.
- Fountoulakis, K. N., Siamouli, M., Kantartzis, S., . (2006). Acute dystonia with low-dosage aripiprazole in Tourette's disorder. The Annals of Pharmacotherapy, 40, 775–777.
- Friedman, J. H., Berman, R. M., Goetz, C. G., . (2006). Open-label flexible dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis with Parkinson's disease. Movement Disorders, 21, 2078–2081.
- Gentile, S. (2007). Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. Journal of Clinical Psychopharmacology, 27, 35–45.
- Gupta, S., & Masand, P. (2004). Aripiprazole: Review of its pharmacology and therapeutic use in psychiatric disorder. Annals of Clinical Psychiatry, 16, 155–166.
- Hammerman, S., Lam, C., & Caroff, S. N. (2006). Neuroleptic malignant syndrome and aripiprazole. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 639–641.
- Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C. A. (2002). The antipsychotic aripiprazole is a potent partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology, 441, 137–140.
- Kane, J. M., Carson, W. H., Saha, A., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., Ali, M. W. (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of Clinical Psychiatry, 63, 763–771.
- Keck, P. E. Jr., Marcus, R., Tourkodimitris, S., Ali, M., Liebeskind, A., Saha, A. Ingenito, G., Aripiprazole Study Group. (2003). A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. The American Journal of Psychiatry, 160, 1651–1658.
- Maytal, G., Ostacher, M., & Stern, T. A. (2006). Aripiprazole-related tardive dyskinesia. CNS Spectrum, 11(6), 435–439.
- Pinninti, N. R., Mago, R., & Adityanjee. (2006). Tardive dystonia-associated prescription of aripiprazole. Journal of Neuropsychiatry Clinical Neurocience, 18(3), 426–427.
- Tamminga, C. A., & Carlsson, A. (2002). Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Current Drug Targets — CNS and Neurological Disorders, 1, 41–147.
- Wickremaratchi, M., Morris, H. R., & Ali, I. M. (2006). Aripiprazole associated with severe exacerbation of Parkinson's disease. Movement Disorders, 21, 1538–1539.